Role of T cells in the pathogenesis of systemic lupus erythematous: Focus on immunometabolism dysfunctions.

[1]  M. Masoumi,et al.  Role of T Cells in the Pathogenesis of Rheumatoid Arthritis: Focus on Immunometabolism Dysfunctions , 2022, Inflammation.

[2]  D. Cui,et al.  mTOR signaling: A pivotal player in Treg cell dysfunction in systemic lupus erythematosus. , 2022, Clinical immunology.

[3]  M. Masoumi,et al.  Immunometabolism Dysfunction in the Pathophysiology and Treatment of Rheumatoid Arthritis. , 2022, Current medicinal chemistry.

[4]  G. Vásquez,et al.  T cell metabolism and possible therapeutic targets in systemic lupus erythematosus: a narrative review , 2022, Immunopharmacology and immunotoxicology.

[5]  I. Chyuan,et al.  Immunometabolism in systemic lupus erythematosus: Relevant pathogenetic mechanisms and potential clinical applications. , 2021, Journal of the Formosan Medical Association = Taiwan yi zhi.

[6]  Xuan Zhang,et al.  Immunometabolic Pathways and Its Therapeutic Implication in Autoimmune Diseases , 2020, Clinical Reviews in Allergy & Immunology.

[7]  M. Masoumi,et al.  Role of glucose metabolism in aggressive phenotype of fibroblast-like synoviocytes: Latest evidence and therapeutic approaches in rheumatoid arthritis. , 2020, International immunopharmacology.

[8]  L. Lv,et al.  Fecal Metabolites Were Altered, Identified as Biomarkers and Correlated With Disease Activity in Patients With Systemic Lupus Erythematosus in a GC-MS-Based Metabolomics Study , 2020, Frontiers in Immunology.

[9]  C. Mohan,et al.  Caution in studying and interpreting the lupus metabolome , 2020, Arthritis Research & Therapy.

[10]  G. Michailidis,et al.  Gut microbiota dysbiosis and altered tryptophan catabolism contribute to autoimmunity in lupus-susceptible mice , 2020, Science Translational Medicine.

[11]  B. Wolf,et al.  Targeting glycosphingolipid metabolism as a potential therapeutic approach for treating disease in female MRL/lpr lupus mice , 2020, PloS one.

[12]  You-ying Mao,et al.  Immunometabolism in the pathogenesis of systemic lupus erythematosus , 2020, Journal of translational autoimmunity.

[13]  G. Tsokos,et al.  T cell Metabolism in Lupus , 2020, Immunometabolism.

[14]  A. Sharabi,et al.  T cell metabolism: new insights in systemic lupus erythematosus pathogenesis and therapy , 2020, Nature Reviews Rheumatology.

[15]  S. Sui,et al.  The CD38/NAD/SIRTUIN1/EZH2 Axis Mitigates Cytotoxic CD8 T Cell Function and Identifies Patients with SLE Prone to Infections , 2020, Cell reports.

[16]  G. Tsokos,et al.  Metabolic control of T cells in autoimmunity. , 2019, Current opinion in rheumatology.

[17]  Vaishali R. Moulton,et al.  Splicing factor SRSF1 controls T cell hyperactivity and systemic autoimmunity. , 2019, The Journal of clinical investigation.

[18]  Nicole M. Chapman,et al.  Metabolic coordination of T cell quiescence and activation , 2019, Nature Reviews Immunology.

[19]  G. Tsokos,et al.  Pyruvate kinase M2 is requisite for Th1 and Th17 differentiation. , 2019, JCI insight.

[20]  T. Dörner,et al.  Novel paradigms in systemic lupus erythematosus , 2019, The Lancet.

[21]  G. Bertsias,et al.  Immunometabolism: an overview and therapeutic prospects in autoimmune diseases. , 2019, Immunotherapy.

[22]  K. Fujio,et al.  Metabolism as a key regulator in the pathogenesis of systemic lupus erythematosus. , 2019, Seminars in arthritis and rheumatism.

[23]  K. Furukawa,et al.  Calcium/calmodulin-dependent protein kinase 4 promotes GLUT1-dependent glycolysis in systemic lupus erythematosus. , 2018 .

[24]  L. Morel,et al.  Targeting T Cell Activation and Lupus Autoimmune Phenotypes by Inhibiting Glucose Transporters , 2019, Front. Immunol..

[25]  R. Müller,et al.  The Translational Machinery of Human CD4+ T Cells Is Poised for Activation and Controls the Switch from Quiescence to Metabolic Remodeling. , 2018, Cell metabolism.

[26]  Youming Peng,et al.  Piperine ameliorated lupus nephritis by targeting AMPK‐mediated activation of NLRP3 inflammasome , 2018, International immunopharmacology.

[27]  S. Salek-Ardakani,et al.  Inhibition of glucose metabolism selectively targets autoreactive follicular helper T cells , 2018, Nature Communications.

[28]  G. Tsokos,et al.  Pyruvate dehydrogenase phosphatase catalytic subunit 2 limits Th17 differentiation , 2018, Proceedings of the National Academy of Sciences.

[29]  A. Thielke,et al.  Nitro-fatty acids are formed in response to virus infection and are potent inhibitors of STING palmitoylation and signaling , 2018, Proceedings of the National Academy of Sciences.

[30]  J. Gottenberg,et al.  Defective BTLA functionality is rescued by restoring lipid metabolism in lupus CD4+ T cells. , 2018, JCI insight.

[31]  Rhea Bhargava,et al.  CaMK4 compromises podocyte function in autoimmune and nonautoimmune kidney disease , 2018, The Journal of clinical investigation.

[32]  N. Huang,et al.  Metabolism as a Target for Modulation in Autoimmune Diseases. , 2018, Trends in immunology.

[33]  Vaishali R. Moulton,et al.  Aberrant T Cell Signaling and Subsets in Systemic Lupus Erythematosus , 2018, Front. Immunol..

[34]  J. Sibilia,et al.  Mitochondria: An Organelle of Bacterial Origin Controlling Inflammation , 2018, Front. Immunol..

[35]  S. Faraone,et al.  Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial , 2018, The Lancet.

[36]  G. Tsokos,et al.  Transcriptional factor ICER promotes glutaminolysis and the generation of Th17 cells , 2018, Proceedings of the National Academy of Sciences.

[37]  G. Hardiman,et al.  CD38-NAD+Axis Regulates Immunotherapeutic Anti-Tumor T Cell Response. , 2018, Cell metabolism.

[38]  Sheng-Cai Lin,et al.  AMPK: Sensing Glucose as well as Cellular Energy Status. , 2017, Cell metabolism.

[39]  M. Mahmoudi,et al.  Epigenetic involvement in etiopathogenesis and implications in treatment of systemic lupus erythematous , 2017, Inflammation Research.

[40]  Q. Lu,et al.  Epigenetics of CD4+ T cells in autoimmune diseases , 2017, Current opinion in rheumatology.

[41]  D. Klatzmann,et al.  T cells and autoimmune kidney disease , 2017, Nature Reviews Nephrology.

[42]  Michael D. Buck,et al.  Metabolic Instruction of Immunity , 2017, Cell.

[43]  L. Morel.  Immunometabolism in systemic lupus erythematosus , 2017, Nature Reviews Rheumatology.

[44]  Hyeon-Beom Seo,et al.  Metformin Suppresses Systemic Autoimmunity in Roquinsan/san Mice through Inhibiting B Cell Differentiation into Plasma Cells via Regulation of AMPK/mTOR/STAT3 , 2017, The Journal of Immunology.

[45]  Kathleen E. Sullivan,et al.  New insights into the immunopathogenesis of systemic lupus erythematosus , 2016, Nature Reviews Rheumatology.

[46]  N. Huang,et al.  Activation of the Mechanistic Target of Rapamycin in SLE: Explosion of Evidence in the Last Five Years , 2016, Current Rheumatology Reports.

[47]  C. Leslie,et al.  Aerobic glycolysis promotes T helper 1 cell differentiation through an epigenetic mechanism , 2016, Science.

[48]  S. Landas,et al.  Mitochondrial Dysfunction in the Liver and Antiphospholipid Antibody Production Precede Disease Onset and Respond to Rapamycin in Lupus‐Prone Mice , 2016, Arthritis & rheumatology.

[49]  L. Morel,et al.  Immune Cell Metabolism in Systemic Lupus Erythematosus , 2016, Current Rheumatology Reports.

[50]  T. Mayadas,et al.  ICER is requisite for Th17 differentiation , 2016, Nature Communications.

[51]  Scott A. Brown,et al.  mTORC1 and mTORC2 Kinase Signaling and Glucose Metabolism Drive Follicular Helper T Cell Differentiation. , 2016, Immunity.

[52]  A. Sharabi,et al.  Empowering Regulatory T Cells in Autoimmunity. , 2016, Trends in molecular medicine.

[53]  T. Nanki,et al.  Serum Resistin Level and Progression of Atherosclerosis during Glucocorticoid Therapy for Systemic Autoimmune Diseases , 2016, Metabolites.

[54]  M. Loriot,et al.  The effect of immunosuppressive molecules on T-cell metabolic reprogramming. , 2016, Biochimie.

[55]  Johan Trygg,et al.  Metabolic Profiling of Systemic Lupus Erythematosus and Comparison with Primary Sjögren’s Syndrome and Systemic Sclerosis , 2016, PloS one.

[56]  O. Kretz,et al.  Mitochondrial Dynamics Controls T Cell Fate through Metabolic Programming , 2016, Cell.

[57]  T. Höfer,et al.  A Cholesterol-Based Allostery Model of T Cell Receptor Phosphorylation. , 2016, Immunity.

[58]  Marco Craveiro,et al.  Cell surface Glut1 levels distinguish human CD4 and CD8 T lymphocyte subsets with distinct effector functions , 2016, Scientific Reports.

[59]  Wei Yang,et al.  Potentiating the antitumour response of CD8+ T cells by modulating cholesterol metabolism , 2016, Nature.

[60]  A. Perl.  Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases , 2016, Nature Reviews Rheumatology.

[61]  F. Carbone,et al.  The Proteomic Landscape of Human Ex Vivo Regulatory and Conventional T Cells Reveals Specific Metabolic Requirements , 2016, Immunity.

[62]  H. Ueno,et al.  T follicular helper (Tfh) cells in lupus: Activation and involvement in SLE pathogenesis , 2016, European journal of immunology.

[63]  D. Teachey,et al.  Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial. , 2016, Blood.

[64]  B. Croker,et al.  Glucose Oxidation Is Critical for CD4+ T Cell Activation in a Mouse Model of Systemic Lupus Erythematosus , 2016, The Journal of Immunology.

[65]  G. Tsokos,et al.  Protein phosphatase 2A is requisite for the function of regulatory T cells , 2015, Nature Immunology.

[66]  Takahisa Suzuki,et al.  Lupus Nephritis IgG Induction of Calcium/Calmodulin‐Dependent Protein Kinase IV Expression in Podocytes and Alteration of Their Function , 2015, Arthritis & rheumatology.

[67]  L. Morel,et al.  Metabolic Factors that Contribute to Lupus Pathogenesis. , 2016, Critical reviews in immunology.

[68]  David K. Finlay,et al.  Immunometabolism: Cellular Metabolism Turns Immune Regulator* , 2015, The Journal of Biological Chemistry.

[69]  John P. Ray,et al.  The Interleukin-2-mTORc1 Kinase Axis Defines the Signaling, Differentiation, and Metabolism of T Helper 1 and Follicular B Helper T Cells. , 2015, Immunity.

[70]  Russell G. Jones,et al.  Attenuation of AMPK signaling by ROQUIN promotes T follicular helper cell formation , 2015, eLife.

[71]  M. Buck,et al.  T cell metabolism drives immunity , 2015, The Journal of experimental medicine.

[72]  K. Yokote,et al.  Obesity Drives Th17 Cell Differentiation by Inducing the Lipid Metabolic Kinase, ACC1. , 2015, Cell reports.

[73]  K. Waddington,et al.  Liver X receptors in immune cell function in humans. , 2015, Biochemical Society transactions.

[74]  Yue-ying Gu,et al.  Neutrophil Extracellular Trap Mitochondrial DNA and Its Autoantibody in Systemic Lupus Erythematosus and a Proof‐of‐Concept Trial of Metformin , 2015, Arthritis & rheumatology.

[75]  Nina Wronkowitz,et al.  DPP4 in Diabetes , 2015, Front. Immunol..

[76]  M. Mahmoudi,et al.  Methyl-CpG-Binding Protein 2 (MECP2) Polymorphism in Iranian Patients with Systemic Lupus Erythematosus , 2015, Inflammation.

[77]  A. Perl,et al.  Oxidative stress and Treg depletion in lupus patients with anti-phospholipid syndrome. , 2015, Clinical immunology.

[78]  J. Oates,et al.  Renal glycosphingolipid metabolism is dysfunctional in lupus nephritis. , 2015, Journal of the American Society of Nephrology : JASN.

[79]  Vaishali R. Moulton,et al.  T cell signaling abnormalities contribute to aberrant immune cell function and autoimmunity. , 2015, The Journal of clinical investigation.

[80]  Andreas Jönsen,et al.  Type I Interferon-Mediated Skewing of the Serotonin Synthesis Is Associated with Severe Disease in Systemic Lupus Erythematosus , 2015, PloS one.

[81]  R. Casellas,et al.  MicroRNA-146a regulates ICOS–ICOSL signalling to limit accumulation of T follicular helper cells and germinal centres , 2015, Nature Communications.

[82]  D. Wallace,et al.  Essential role of mitochondrial energy metabolism in Foxp3+ T‐regulatory cell function and allograft survival , 2015, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[83]  B. Croker,et al.  Normalization of CD4+ T cell metabolism reverses lupus , 2015, Science Translational Medicine.

[84]  E. Matteson,et al.  T-cell metabolism in autoimmune disease , 2015, Arthritis Research & Therapy.

[85]  P. Toogood,et al.  Sterol metabolism controls T(H)17 differentiation by generating endogenous RORγ agonists. , 2015, Nature chemical biology.

[86]  A. Lane,et al.  Regulation of mammalian nucleotide metabolism and biosynthesis , 2015, Nucleic acids research.

[87]  J. Asara,et al.  Comprehensive metabolome analyses reveal N-acetylcysteine-responsive accumulation of kynurenine in systemic lupus erythematosus: implications for activation of the mechanistic target of rapamycin , 2015, Metabolomics.

[88]  D. Wirth,et al.  Dietary restriction protects against experimental cerebral malaria via leptin modulation and T cell mTORC1 suppression , 2014, Nature Communications.

[89]  B. Pasquier.  Autophagy inhibitors , 2015, Cellular and Molecular Life Sciences.

[90]  B. Tönshoff,et al.  Akt-Dependent Enhanced Migratory Capacity of Th17 Cells from Children with Lupus Nephritis , 2014, The Journal of Immunology.

[91]  G. Tsokos,et al.  KN-93, an inhibitor of calcium/calmodulin-dependent protein kinase IV, promotes generation and function of Foxp3+ regulatory T cells in MRL/lpr mice , 2014, Autoimmunity.

[92]  Nataliya Gorinski,et al.  De novo fatty acid synthesis controls the fate between regulatory T and T helper 17 cells , 2014, Nature Medicine.

[93]  C. Baldari,et al.  Statins: from cholesterol-lowering drugs to novel immunomodulators for the treatment of Th17-mediated autoimmune diseases. , 2014, Pharmacological research.

[94]  J. Rathmell,et al.  Metabolic Reprogramming towards Aerobic Glycolysis Correlates with Greater Proliferative Ability and Resistance to Metabolic Inhibition in CD8 versus CD4 T Cells , 2014, PloS one.

[95]  E. Higashihara,et al.  Zoledronic acid improves clinical outcomes in patients with bone metastatic hormone-naïve prostate cancer in a multicenter clinical trial. , 2014, Anticancer research.

[96]  G. Nicolson.  Mitochondrial Dysfunction and Chronic Disease: Treatment With Natural Supplements. , 2014, Integrative medicine.

[97]  A. Perl,et al.  Increased mitochondrial electron transport chain activity at complex I is regulated by N-acetylcysteine in lymphocytes of patients with systemic lupus erythematosus. , 2014, Antioxidants & redox signaling.

[98]  Jae-Hoon Chang,et al.  Inflammatory T cell responses rely on amino acid transporter ASCT2 facilitation of glutamine uptake and mTORC1 kinase activation. , 2014, Immunity.

[99]  T. Rauen,et al.  CaMK4-dependent activation of AKT/mTOR and CREM-α underlies autoimmunity-associated Th17 imbalance. , 2014, The Journal of clinical investigation.

[100]  D. Isenberg,et al.  Normalizing glycosphingolipids restores function in CD4+ T cells from lupus patients. , 2014, The Journal of clinical investigation.

[101]  G. Canaud,et al.  Inhibition of the mTORC pathway in the antiphospholipid syndrome. , 2014, The New England journal of medicine.

[102]  Chih-Hao Chang,et al.  Fueling Immunity: Insights into Metabolism and Lymphocyte Function , 2013, Science.

[103]  M. Kretzler,et al.  The peroxisome-proliferator activated receptor-γ agonist pioglitazone modulates aberrant T cell responses in systemic lupus erythematosus. , 2013, Clinical immunology.

[104]  S. Faraone,et al.  Mechanistic Target of Rapamycin Activation Triggers IL-4 Production and Necrotic Death of Double-Negative T Cells in Patients with Systemic Lupus Erythematosus , 2013, The Journal of Immunology.

[105]  Peter Vogel,et al.  mTORC1 couples immune signals and metabolic programming to establish Treg cell function , 2013, Nature.

[106]  F. Malavasi,et al.  Increased CD38 expression in T cells and circulating anti-CD38 IgG autoantibodies differentially correlate with distinct cytokine profiles and disease activity in systemic lupus erythematosus patients. , 2013, Cytokine.

[107]  Linda V. Sinclair,et al.  Control of amino-acid transport by antigen receptors coordinates the metabolic reprogramming essential for T cell differentiation , 2013, Nature Immunology.

[108]  S. Koyasu,et al.  Role of PI3K/Akt and mTOR complexes in Th17 cell differentiation , 2013, Annals of the New York Academy of Sciences.

[109]  J. Licht,et al.  Mitochondria are required for antigen-specific T cell activation through reactive oxygen species signaling. , 2013, Immunity.

[110]  T. Hasunuma,et al.  Resistin is associated with the inflammation process in patients with systemic autoimmune diseases undergoing glucocorticoid therapy: comparison with leptin and adiponectin , 2013, Modern rheumatology.

[111]  G. Tsokos,et al.  Calcium/Calmodulin-Dependent Protein Kinase IV Suppresses IL-2 Production and Regulatory T Cell Activity in Lupus , 2012, The Journal of Immunology.

[112]  Stephen V Faraone,et al.  N-acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial. , 2012, Arthritis and rheumatism.

[113]  T. Caza,et al.  Metabolic regulation of organelle homeostasis in lupus T cells. , 2012, Clinical immunology.

[114]  David K. Finlay,et al.  Regulation of glucose metabolism in T cells: new insight into the role of Phosphoinositide 3-kinases , 2012, Front. Immun..

[115]  J. Craft.  Follicular helper T cells in immunity and systemic autoimmunity , 2012, Nature Reviews Rheumatology.

[116]  Rahul Shinde,et al.  Tolerance to apoptotic cells is regulated by indoleamine 2,3-dioxygenase , 2012, Proceedings of the National Academy of Sciences.

[117]  D. Green,et al.  The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. , 2011, Immunity.

[118]  E. Robak,et al.  [Current views on etiopathogenesis of systemic lupus erythematosus]. , 2011, Postepy higieny i medycyny doswiadczalnej.

[119]  M. Dwyer,et al.  Estrogen-related receptor-α is a metabolic regulator of effector T-cell activation and differentiation , 2011, Proceedings of the National Academy of Sciences.

[120]  T. Kishimoto,et al.  Lack of B and T lymphocyte attenuator exacerbates autoimmune disorders and induces Fas-independent liver injury in MRL-lpr/lpr mice. , 2011, International immunology.

[121]  P. Worley,et al.  The mammalian Target of Rapamycin (mTOR) regulates T helper cell differentiation through the selective activation of mTORC1 and mTORC2 signaling , 2011, Nature Immunology.

[122]  J. Rathmell,et al.  Cutting Edge: Distinct Glycolytic and Lipid Oxidative Metabolic Programs Are Essential for Effector and Regulatory CD4+ T Cell Subsets , 2011, The Journal of Immunology.

[123]  I. Joosten,et al.  Mycophenolic Acid‐Mediated Suppression of Human CD4+ T Cells: More Than Mere Guanine Nucleotide Deprivation , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[124]  K. Stylianou,et al.  The PI3K/Akt/mTOR pathway is activated in murine lupus nephritis and downregulated by rapamycin. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[125]  G. Tsokos,et al.  Suppression of autoimmunity and organ pathology in lupus-prone mice upon inhibition of calcium/calmodulin-dependent protein kinase type IV. , 2011, Arthritis and rheumatism.

[126]  B. Javierre,et al.  A new epigenetic challenge: systemic lupus erythematosus. , 2011, Advances in experimental medicine and biology.

[127]  F. Fallarino,et al.  IDO Upregulates Regulatory T Cells via Tryptophan Catabolite and Suppresses Encephalitogenic T Cell Responses in Experimental Autoimmune Encephalomyelitis , 2010, The Journal of Immunology.

[128]  G. Gilkeson,et al.  Impact of Fli‐1 transcription factor on autoantibody and lupus nephritis in NZM2410 mice , 2010, Clinical and experimental immunology.

[129]  Kotaro Suzuki,et al.  B and T Lymphocyte Attenuator Suppresses IL-21 Production from Follicular Th Cells and Subsequent Humoral Immune Responses , 2010, The Journal of Immunology.

[130]  A. Opipari,et al.  Characterization of the metabolic phenotype of chronically activated lymphocytes , 2010, Lupus.

[131]  Jeff E. Mold,et al.  Tryptophan Catabolism by Indoleamine 2,3-Dioxygenase 1 Alters the Balance of TH17 to Regulatory T Cells in HIV Disease , 2010, Science Translational Medicine.

[132]  James L. Park,et al.  The Peroxisome Proliferator-Activated Receptor γ Agonist Pioglitazone Improves Cardiometabolic Risk and Renal Inflammation in Murine Lupus1 , 2009, The Journal of Immunology.

[133]  P. Worley,et al.  The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. , 2009, Immunity.

[134]  Mark S. Sundrud,et al.  Halofuginone Inhibits TH17 Cell Differentiation by Activating the Amino Acid Starvation Response , 2009, Science.

[135]  David R Fernandez,et al.  Metabolic control of T cell activation and death in SLE. , 2009, Autoimmunity reviews.

[136]  Wei Liu,et al.  Mapping similarities in mTOR pathway perturbations in mouse lupus nephritis models and human lupus nephritis , 2008, Arthritis research & therapy.

[137]  Q. Lu,et al.  Abnormal histone modification patterns in lupus CD4+ T cells. , 2008, The Journal of rheumatology.

[138]  J. Rathmell,et al.  Glucose Uptake Is Limiting in T Cell Activation and Requires CD28-Mediated Akt-Dependent and Independent Pathways1 , 2008, The Journal of Immunology.

[139]  S. Tam,et al.  Rapamycin prevents the development of nephritis in lupus-prone NZB/W F1 mice , 2008, Lupus.

[140]  Jerry L. Workman,et al.  Histone acetyltransferase complexes: one size doesn't fit all , 2007, Nature Reviews Molecular Cell Biology.

[141]  A. Penfornis,et al.  Immunosuppressive drug-induced diabetes. , 2006, Diabetes & metabolism.

[142]  A. Perl,et al.  Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus. , 2006, Arthritis and rheumatism.

[143]  Craig B. Thompson,et al.  Fuel feeds function: energy metabolism and the T-cell response , 2005, Nature Reviews Immunology.

[144]  Anthony E. Boitano,et al.  Identification and validation of the mitochondrial F1F0-ATPase as the molecular target of the immunomodulatory benzodiazepine Bz-423. , 2005, Chemistry & biology.

[145]  C. Mawrin,et al.  Systemic lupus erythematosus serum IgG increases CREM binding to the IL-2 promoter and suppresses IL-2 production through CaMKIV. , 2005, The Journal of clinical investigation.

[146]  A. Lanfranco,et al.  CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms , 2004, Molecular and Cellular Biology.

[147]  G. Gilkeson,et al.  Decreased Expression of the Ets Family Transcription Factor Fli-1 Markedly Prolongs Survival and Significantly Reduces Renal Disease in MRL/lpr Mice1 , 2004, The Journal of Immunology.

[148]  M. Nambiar,et al.  Alterations in Lipid Raft Composition and Dynamics Contribute to Abnormal T Cell Responses in Systemic Lupus Erythematosus12 , 2004, The Journal of Immunology.

[149]  T. Vial,et al.  Immunosuppressive drugs and cancer. , 2003, Toxicology.

[150]  G. Glick,et al.  Attenuation of autoimmune disease in Fas-deficient mice by treatment with a cytotoxic benzodiazepine. , 2003, Arthritis and rheumatism.

[151]  G. Gilkeson,et al.  Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. , 2003, The Journal of clinical investigation.

[152]  Anthony E. Boitano,et al.  Benzodiazepine-induced superoxide signals B cell apoptosis: mechanistic insight and potential therapeutic utility. , 2002, The Journal of clinical investigation.

[153]  A. Perl,et al.  Persistent Mitochondrial Hyperpolarization, Increased Reactive Oxygen Intermediate Production, and Cytoplasmic Alkalinization Characterize Altered IL-10 Signaling in Patients with Systemic Lupus Erythematosus1 , 2002, The Journal of Immunology.

[154]  C. Thompson,et al.  The CD28 signaling pathway regulates glucose metabolism. , 2002, Immunity.

[155]  A. Perl,et al.  Mitochondrial hyperpolarization and ATP depletion in patients with systemic lupus erythematosus. , 2002, Arthritis and rheumatism.

[156]  W. Bennett,et al.  Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[157]  E. Rothenberg,et al.  Precise developmental regulation of Ets family transcription factors during specification and commitment to the T cell lineage. , 1999, Development.

[158]  D. Fuchs,et al.  Degradation of tryptophan in patients with systemic lupus erythematosus. , 1999, Advances in experimental medicine and biology.

[159]  B. Walgreen,et al.  Attenuation of murine lupus nephritis by mycophenolate mofetil. , 1998, Journal of the American Society of Nephrology : JASN.

[160]  R. Ferrari,et al.  Rheumatology guidebook : a step-by-step guide to diagnosis and treatment , 1996 .

[161]  A. Bernstein,et al.  An immunological renal disease in transgenic mice that overexpress Fli-1, a member of the ets family of transcription factor genes , 1995, Molecular and cellular biology.

[162]  H. Gendelman,et al.  Tumor necrosis factor alpha-induced apoptosis in human neuronal cells: protection by the antioxidant N-acetylcysteine and the genes bcl-2 and crmA , 1995, Molecular and cellular biology.

[163]  S. Aichinger,et al.  Cell-cycle-related metabolic and enzymatic events in proliferating rat thymocytes. , 1988, European journal of biochemistry.

[164]  D. Roos,et al.  Changes in the carbohydrate metabolism of mitogenically stimulated human peripheral lymphocytes. II. Relative importance of glycolysis and oxidative phosphorylation on phytohaemagglutinin stimulation. , 1973, Experimental cell research.